TY  - JOUR
AU  - Serrano-Falcón, Blanca
AU  - Delgado-Aros, Sílvia
AU  - Mearin, Fermín
AU  - Ciriza de Los Ríos, Constanza
AU  - Serra, Jordi
AU  - Mínguez, Miguel
AU  - Montoro Huguet, Miguel
AU  - Perelló, Antonia
AU  - Santander, Cecilio
AU  - Pérez Aisa, Ángeles
AU  - Bañón-Rodríguez, Inmaculada
AU  - Rey, Enrique
PY  - 2019
DO  - 10.1177/1756284819857358
SN  - 1756-283X
UR  - https://hdl.handle.net/10668/26706
T2  - Therapeutic advances in gastroenterology
AB  - Linaclotide is approved for the treatment of moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C) in adults. This study aimed to assess factors predictive of a clinical response and improvements in non-IBS symptoms with...
LA  - en
KW  - abdominal pain
KW  - constipation
KW  - functional gastrointestinal diseases
KW  - irritable bowel syndrome
TI  - Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms.
TY  - research article
VL  - 12
ER  -